The ACRIN 6657-extension trial, the first multi-center trial using magnetic resonance spectroscopy (MRS) in breast cancer, has completed and its initial results have been recently published. This study reports on the quality of the MRS data and identifies technical and logistic factors that contributed to a lower-than-anticipated data yield.
This abstract and the presentation materials are available to members only; a login is required.